ZET-Speech: Zero-shot adaptive Emotion-controllable Text-to-Speech Synthesis with Diffusion and Style-based Models

Emotional Text-To-Speech (TTS) is an important task in the development of systems (e.g., human-like dialogue agents) that require natural and emotional speech. Existing approaches, however, only aim to produce emotional TTS for seen speakers during training, without consideration of the generalization to unseen speakers. In this paper, we propose ZET-Speech, a zero-shot adaptive emotion-controllable TTS model that allows users to synthesize any speaker's emotional speech using only a short, neutral speech segment and the target emotion label. Specifically, to enable a zero-shot adaptive TTS model to synthesize emotional speech, we propose domain adversarial learning and guidance methods on the diffusion model. Experimental results demonstrate that ZET-Speech successfully synthesizes natural and emotional speech with the desired emotion for both seen and unseen speakers. Samples are at https://ZET-Speech.github.io/ZET-Speech-Demo/.Comment: Accepted by INTERSPEECH 202

A unique bleeding-related complication of sorafenib, a tyrosine kinase inhibitor, in advanced hepatocellular carcinoma: a case report

INTRODUCTION: Sorafenib, a multikinase inhibitor as a standard of care for advanced hepatocellular carcinoma, may lead endothelial cells to an unstable state by blocking the signaling pathway of vascular endothelial growth factor receptor, which may result in the disruption of the architecture and integrity of the microvasculature, and eventually increase the risk of hemorrhage. Hemobilia is a relatively uncommon condition as a consequence of hepatocellular carcinoma and its risk factors remain uncertain. CASE PRESENTATION: Here we report a unique case of hemobilia occurring in a 55-year-old Korean man with hepatitis B virus-related hepatocellular carcinoma on Barcelona Clinic Liver Cancer advanced stage after seven days of treatment with sorafenib. He had received prior radiation therapy. Endoscopy revealed bleeding from the major duodenal papilla and endoscopic retrograde cholangiography revealed an amorphous filling defect throughout the common bile duct. Blood clots were removed by balloon sweeping and a nasobiliary drainage tube was placed. No further bleeding has been detected as of eight months after discontinuation of sorafenib. CONCLUSION: Sorafenib may increase the risk of biliary bleeding in hepatocellular carcinoma patients who were primed with irradiation, by blocking the signaling pathway of the vascular endothelial growth factor receptor. Therefore, sorafenib should be used with caution in patients with advanced hepatocellular carcinoma, especially when combined with radiation therapy